Moderate doses of interferon alpha 2b with concurrent hydroxyurea in patients of chronic myeloid leukemia benefits early, late chronic phase and acelerated phase: Five year follow up

Ranga Rao Rangaraju*, Subramanya Y. Sarma, Lakhtakia Ritu, Nandi Jayasree

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Moderate doses of interferon alpha 2b with concurrent hydroxyurea in patients of chronic myeloid leukemia benefits early, late chronic phase and acelerated phase: Five year follow up'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds